<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527875</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZSLC24</org_study_id>
    <nct_id>NCT03527875</nct_id>
  </id_info>
  <brief_title>Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients</brief_title>
  <official_title>Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients: A Multi-center, Prospective, Open-labeled, Cohort Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of different methods of
      preoperative biliary drainage in hilar cholangiocarcinoma patients, including PTBD
      (Percutaneous Transhepatic Biliary Drainage), ENBD (Endoscopic Nasobiliary Drainage) and EBS
      (Endoscopic Biliary Stenting).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication rate after drainage</measure>
    <time_frame>From PBD to completion of radical surgery, an average of 1 month</time_frame>
    <description>Complication rate between PBD (preoperative biliary drainage) and radical surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate after radical surgery</measure>
    <time_frame>1 month post operatively</time_frame>
    <description>Complication rate after radical surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate of PBD</measure>
    <time_frame>Day 1</time_frame>
    <description>Success rate of different methods of PBD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>Day 1</time_frame>
    <description>duration of radical surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatoduodenal edema</measure>
    <time_frame>at time of radical surgery</time_frame>
    <description>Degree of hepatoduodenal edema (including no edema, mild edema, moderate edema, and severe edema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality</measure>
    <time_frame>from PBD to 4 weeks after surgery, an average of 2 month</time_frame>
    <description>Mortality between PBD and 4 weeks after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation metastasis</measure>
    <time_frame>Day 1</time_frame>
    <description>Rate of implantation metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Total bilirubin</measure>
    <time_frame>2 weeks after PBD</time_frame>
    <description>Recovery efficiency of liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in alanine aminotransferase</measure>
    <time_frame>2 weeks after PBD</time_frame>
    <description>Recovery efficiency of liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in aspartate aminotransferase</measure>
    <time_frame>2 weeks after PBD</time_frame>
    <description>Recovery efficiency of liver function</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Jaundice, Obstructive</condition>
  <condition>Klatskin Tumor</condition>
  <arm_group>
    <arm_group_label>PTBD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Transhepatic Biliary Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENBD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Nasobiliary Biliary Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Biliary Stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTBD group</intervention_name>
    <description>Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients</description>
    <arm_group_label>PTBD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ENBD group</intervention_name>
    <description>Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients</description>
    <arm_group_label>ENBD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBS group</intervention_name>
    <description>Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients</description>
    <arm_group_label>EBS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who meet the following criteria are included into the study:

               1. with Preoperative clinical diagnosis of hilar cholangiocarcinoma, no distant
                  metastasis or peripheral vascular invasion, and plan to receive radical hilar
                  cholangiocarcinoma resection.

               2. Serum total bilirubin is higher than 200 umol/l.

               3. Sign informed consent to receive preoperative PTBD, ENBD, or EBS.

        Exclusion Criteria:

          -  If any of the following items are met, the subject cannot enter the study.

               1. with Concurrent cholangitis;

               2. have received PTBD, ENBD, or EBS before;

               3. have received neoadjuvant chemotherapy

               4. Age less than 18 years old or older than 80 years old

               5. with severe mental illness or severe heart, lung, kidney insufficiency and cannot
                  tolerate surgery;

               6. with some other malignant diseases (such as other primary malignant tumors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Houbao Liu, PHD</last_name>
    <phone>13818971698</phone>
    <email>houbaoliu@aliyun.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

